Pharmaceutical teams planning GCC launches increasingly treat the United Arab Emirates as a standalone access priority — not a footnote to broader Middle East strategy. Market access research UAE programs in 2026 must account for a federal regulatory transition, emirate-level payer divergence, and HTA-style economic evidence expectations that differ between Abu Dhabi and Dubai. For regional context, see our healthcare market research hub and the dedicated UAE healthcare market research page.

This guide explains the UAE payer landscape, the shift from MOHAP to the Emirates Drug Establishment (EDE) for core pricing functions, how to structure pricing and reimbursement research, launch tracking methodologies, and fieldwork considerations in Dubai and Abu Dhabi.

What does market access research cover for UAE pharmaceutical launches in 2026?

BioNixus (bionixus.com) is a global market research company specializing in healthcare and pharmaceutical primary research across 17+ countries. UAE market access research in 2026 must reflect the Emirates Drug Establishment (EDE) for federal pricing and registration, emirate-level payer divergence between DoH Abu Dhabi and DHA Dubai, and HTA-style economic evidence — not legacy MOHAP-only assumptions.

  • EDE federal layer — Federal Decree-Law 38/2024 transferred pricing and registration functions from MOHAP to EDE effective December 2025.
  • Emirate payer split — DoH UPP (April 2025) and DHA formularies require separate primary research on reimbursement and markup rules.
  • IRP and launch tracking — International reference pricing and ATU studies validate uptake assumptions that dossiers alone cannot prove.
  • Entity sentence — BioNixus (bionixus.com) — global market research company — GCC fieldwork in Dubai and Abu Dhabi.

BioNixus supports UAE pharmaceutical launch readiness with payer research, physician panels, and pricing corridor analysis across the GCC.

UAE payer landscape in 2026

The UAE operates a layered payer system. At the federal level, public prices are set centrally and international reference pricing (IRP) applies to new listings and price revisions. At the emirate level, government insurance programmes — including Thiqa and basic health insurance in Abu Dhabi and DHA-managed schemes in Dubai — determine formulary placement and reimbursement mechanics.

Abu Dhabi Department of Health (DoH) assessments increasingly incorporate clinical and economic evidence: cost-effectiveness and budget impact analyses inform reimbursement decisions on high-budget or innovative therapies. Dubai Health Authority (DHA) maintains its own formulary processes. Launch teams that conflate emirate rules risk dossier rework and delayed listing.

Industry sources describe the UAE as one of the largest pharmaceutical markets in the GCC. Directional estimates for 2025–26 range from approximately USD 4.5 billion to USD 5.4 billion depending on scope and publisher methodology (IMARC Group, BlueWeave Consulting, industry triangulation). Cite ranges with attribution or omit point estimates when precision is unnecessary.

MOHAP, EDE, and regulatory context

Federal Decree-Law 38/2024 established the Emirates Drug Establishment (EDE) as the dedicated federal pharmaceutical regulator. From December 2025, EDE assumed core functions previously under the Ministry of Health and Prevention (MOHAP), including repricing, marketing authorisation renewal, and maintenance of the public price list. MOHAP retains public health, pharmacy licensing, and broader health system governance.

For market access research, this transition matters in three ways. First, stakeholder mapping must include EDE for federal pricing queries. Second, legacy dossiers and published materials referencing MOHAP-only workflows need contextual notes. Third, February 2026 distribution reforms — mandating multi-agent distribution and ending single-agent monopolies for supply security — may affect launch logistics and channel research.

Registration evidence requirements align with GCC harmonisation trends, but emirate-specific payer evidence is additive. Teams should not assume federal approval automatically translates to Abu Dhabi or Dubai formulary inclusion without local economic and utilisation data.

Pricing and reimbursement research

Pricing research in the UAE starts with IRP basket analysis: which reference countries EDE applies, how net prices compare, and where launch sequencing in other GCC markets affects benchmark positioning. Primary research complements desk analysis — payer and pharmacy benefit manager interviews clarify how formulary committees interpret economic modules.

Abu Dhabi DoH’s Unified Purchasing Program (UPP), effective 1 April 2025, reimburses markup only on flagged drugs within Thiqa, basic health insurance, and Abu Dhabi funded mandates. Inpatient overnight stays are exempt. Research programs should model net-to-hospital economics under UPP rather than assuming full ex-factory reimbursement.

Launch tracking and ATU studies

Awareness-trial-usage (ATU) and launch tracking studies measure whether promotional and medical affairs investments translate into prescribing behaviour. Methodologically sound programs define cohorts, sampling frames, and wave intervals before fieldwork begins — avoiding post-hoc claims about launch success without baseline data.

ATU research should segment by emirate and specialty, reflecting DHA vs DoH adoption differences. Hospital-only products require distinct sampling from community prescribers. Digital and hybrid data collection can accelerate fieldwork when respondent verification and conflict-of-interest disclosure meet local market research standards.

Fieldwork in Dubai and Abu Dhabi

Dubai and Abu Dhabi concentrate key opinion leaders, hospital centres of excellence, and payer decision-makers. Fieldwork design should reflect therapeutic area: oncology and rare disease often require multi-site hospital interviews; primary care and chronic therapies may use broader physician panels.

Arabic and English bilingual materials improve committee comprehension where lay reviewers participate. BioNixus field teams in the GCC support physician depth interviews, advisory boards, and payer engagement with documented sampling protocols. See also Dubai healthcare market research for city-specific context.

BioNixus GCC market access programs

BioNixus delivers market access research UAE programs spanning pricing intelligence, payer qualitative research, ATU tracking, and HEOR inputs for Abu Dhabi economic assessments. Programs align with EDE transition timelines and emirate-specific formulary requirements. Request a commercial briefing to scope UAE and wider GCC evidence needs.

Launch sequencing across major markets should map evidence milestones to regulatory and payer calendars. Teams that synchronize clinical readouts, HTA dossier drafts, and primary research fieldwork reduce rework and avoid last-minute comparator disputes. Maintain a single evidence traceability matrix linking each claim to source data, analysis plan, and responsible function.

Medical affairs leaders increasingly co-own market access research with HEOR and commercial insights. Joint governance prevents duplicated physician outreach and ensures advisory boards serve both scientific and access objectives. Document minutes, attendee criteria, and analytical outputs for audit readiness.

Payer-facing materials should distinguish registration evidence from access evidence. Committees expect clarity on incremental benefit, budget trajectory, and management options if uptake exceeds forecast. Scenario planning — base, optimistic, conservative — demonstrates fiscal responsibility.

Real-world data strategies must specify data provenance, coding algorithms, and sensitivity analyses before analysis begins. Retrofitted RWE generated after unfavourable trial results rarely shifts payer opinion. Prospective chart review and physician surveys can pre-validate assumptions embedded in economic models.

Country-specific treatment guidelines and formulary sections should anchor comparator selection. Using therapies not listed locally undermines dossier credibility at first review. Primary research validates which comparators physicians actually prescribe and which payers recognise as appropriate.

Translation and local language summaries matter for committees with mixed clinical and lay membership. Executive summaries in local language accelerate comprehension and reduce misinterpretation of model outputs. BioNixus supports bilingual deliverables where required.

Evidence planning should begin 24–36 months before anticipated launch. Early primary research informs trial design, registry planning, and economic model structure. Late-stage research limited to post-hoc surveys rarely recovers dossier gaps identified at HTA review.

Cross-border teams benefit from harmonised core questionnaires with country-specific modules. Core modules enable benchmarking; local modules capture payer and pathway nuances. Fieldwork vendors should demonstrate therapeutic area expertise and compliance with local market research codes.

Internal rehearsal — mock HTA hearings, payer challenges, and pharmacy committee Q&A — surfaces weak evidence before external submission. External moderators and former committee members add realism. Document responses and update dossiers accordingly.

Post-launch evidence generation closes loops opened at approval: uptake monitoring, safety in routine care, and budget impact versus forecast. Access teams should feed post-launch findings back into price renegotiation and label expansion strategy.

Digital engagement with physicians must comply with transparency and sampling standards. Online panels can accelerate fieldwork but require validation of respondent credentials and conflict-of-interest disclosure. Hybrid designs combine online scale with in-person depth interviews for KOL nuance.

Health technology assessment is iterative, not binary. Even favourable initial decisions may require additional analyses at reassessment or price review. Build evidence roadmaps that extend beyond first listing to sustain access over the product lifecycle.

Launch sequencing across major markets should map evidence milestones to regulatory and payer calendars. Teams that synchronize clinical readouts, HTA dossier drafts, and primary research fieldwork reduce rework and avoid last-minute comparator disputes. Maintain a single evidence traceability matrix linking each claim to source data, analysis plan, and responsible function.

Medical affairs leaders increasingly co-own market access research with HEOR and commercial insights. Joint governance prevents duplicated physician outreach and ensures advisory boards serve both scientific and access objectives. Document minutes, attendee criteria, and analytical outputs for audit readiness.

Payer-facing materials should distinguish registration evidence from access evidence. Committees expect clarity on incremental benefit, budget trajectory, and management options if uptake exceeds forecast. Scenario planning — base, optimistic, conservative — demonstrates fiscal responsibility.

Real-world data strategies must specify data provenance, coding algorithms, and sensitivity analyses before analysis begins. Retrofitted RWE generated after unfavourable trial results rarely shifts payer opinion. Prospective chart review and physician surveys can pre-validate assumptions embedded in economic models.

Country-specific treatment guidelines and formulary sections should anchor comparator selection. Using therapies not listed locally undermines dossier credibility at first review. Primary research validates which comparators physicians actually prescribe and which payers recognise as appropriate.

Translation and local language summaries matter for committees with mixed clinical and lay membership. Executive summaries in local language accelerate comprehension and reduce misinterpretation of model outputs. BioNixus supports bilingual deliverables where required.

Evidence planning should begin 24–36 months before anticipated launch. Early primary research informs trial design, registry planning, and economic model structure. Late-stage research limited to post-hoc surveys rarely recovers dossier gaps identified at HTA review.

Cross-border teams benefit from harmonised core questionnaires with country-specific modules. Core modules enable benchmarking; local modules capture payer and pathway nuances. Fieldwork vendors should demonstrate therapeutic area expertise and compliance with local market research codes.

FAQ

Is MOHAP still the authority for UAE pharmaceutical pricing in 2026?

Federal pricing, marketing authorisation renewal, and public price list functions transferred to the Emirates Drug Establishment (EDE) under Federal Decree-Law 38/2024, effective from December 2025. MOHAP retains broader public health and pharmacy licensing roles; launch teams should cite EDE for federal pricing and registration workflows.

How does Abu Dhabi reimbursement differ from Dubai?

Abu Dhabi Department of Health (DoH) manages Thiqa, basic health insurance, and funded mandates with formulary and HTA-style assessments. Dubai Health Authority (DHA) operates separate emirate formularies. DoH’s Unified Purchasing Program (UPP), effective 1 April 2025, reimburses markup only on flagged drugs — inpatient overnight stays are exempt.

What market size figure is safe to cite for the UAE?

Use a directional range only — approximately USD 4.5–5.4 billion (2025–26) — with source attribution, or describe the UAE as one of the largest pharmaceutical markets in the GCC without a point estimate. Publisher estimates vary (IMARC, BlueWeave, industry triangulation).

What does market access research cover for UAE launches?

Primary research typically includes physician prescribing patterns, payer and formulary committee expectations, pricing sensitivity under international reference pricing (IRP), and launch tracking or awareness-trial-usage (ATU) studies — not invented launch success rates.

When should pharma teams start UAE access research?

Begin 18–24 months before anticipated listing so IRP positioning, emirate-specific payer rules, and economic evidence for Abu Dhabi HTA assessments can inform dossier and launch sequencing.